Before entering the private sector in 2005, Governor Thompson enjoyed a long and distinguished career in public service. As Secretary of the U.S. Department of Health and Human Services from 2001 to 2005, he was a leading advocate for the health and welfare of all Americans. He also served four terms as Governor of Wisconsin from 1987 to 2001. Governor Thompson served as Interim President of the University of Wisconsin System from July 2020 through March 2022.
Governor Thompson served as a partner at the law firm of Akin Gump Strauss Hauer & Feld LLP in Washington, D.C. from 2005 until January 2012, and as an Adjunct Senior Advisor from 2017 to 2020. From 2005 to 2009, he also served as the Independent Chair of the Deloitte Center for Health Solutions, which researches and develops solutions to some of our nation’s most pressing health care and public health related challenges. He currently serves on the boards of directors of HealthPeak Properties, Inc. and TherapeuticsMD, Inc., each of which is publicly-traded. He resigned as executive chair of the TherapeuticsMD board in March 2024, and was re-appointed as the non-executive chair of the TherapeuticsMD board. He previously served on the boards of various other public companies, including AGA Medical Holdings, Inc., Cancer Genetics Inc., CareView Communications, Inc., Centene Corporation, CNS Response, Inc., C.R. Bard, Inc., Cytori Therapeutics, Inc., Physicians Realty Trust, Scilex Holding Company, SpectraScience, Tyme Technologies, Inc., and X Shares Advisors.
Governor Thompson earned his bachelor and juris doctor degrees from the University of Wisconsin–Madison.
Governor Thompson brings to our Board significant experience in the healthcare industry, both as a public official (former Secretary of the U.S. Department of Health and Human Services) and in the private sector (Deloitte Center for Health Solutions), as well as public company board experience and knowledge of legislative affairs. Governor Thompson’s legal experience from his private practice at Akin Gump also is useful in our Board’s oversight of our legal and regulatory compliance. Our Board has determined that Governor Thompson meets the financial sophistication requirements of Nasdaq’s listing standards for Audit Committee members.
What is Tommy G. Thompson's net worth?
The estimated net worth of Tommy G. Thompson is at least $2.61 million as of March 24th, 2025. Mr. Thompson owns 8,480 shares of United Therapeutics stock worth more than $2,614,130 as of April 1st. This net worth approximation does not reflect any other investments that Mr. Thompson may own. Learn More about Tommy G. Thompson's net worth.
How do I contact Tommy G. Thompson?
The corporate mailing address for Mr. Thompson and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at ir@unither.com. Learn More on Tommy G. Thompson's contact information.
Has Tommy G. Thompson been buying or selling shares of United Therapeutics?
Tommy G. Thompson has not been actively trading shares of United Therapeutics within the last three months. Most recently, Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a transaction totalling $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. Learn More on Tommy G. Thompson's trading history.
Who are United Therapeutics' active insiders?
United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), Louis Sullivan (Director), and Tommy Thompson (Director). Learn More on United Therapeutics' active insiders.
Are insiders buying or selling shares of United Therapeutics?
During the last twelve months, insiders at the biotechnology company sold shares 79 times. They sold a total of 468,104 shares worth more than $154,564,567.87. The most recent insider tranaction occured on March, 24th when Director Tommy G Thompson sold 2,500 shares worth more than $797,000.00. Insiders at United Therapeutics own 11.9% of the company.
Learn More about insider trades at United Therapeutics. Information on this page was last updated on 3/24/2025.
